Russian Federation vs Singapore: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Russian Federation
0.1%
in 2024
Singapore
0.1%
in 2024
Russian Federation rank
134th
Singapore rank
134th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Russian Federation
- Singapore
How they compare
Russian Federation currently reports 0.1% against 0.1% in Singapore, a difference of 0.0%.
Across all 10 years both countries report, Singapore has been ahead every year.
Russian Federation ranks 134th and Singapore ranks 134th of 246 countries.
Singapore has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Russian Federation | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Singapore |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Russian Federation or Singapore?
- Russian Federation, at 0.1% against 0.1% in Singapore as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Russian Federation and Singapore?
- 0.0%, with Russian Federation ahead.
- How many years of comparable data are there for Russian Federation and Singapore?
- 10 years are reported by both, from 2015 to 2024.
- How do Russian Federation and Singapore rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Russian Federation ranks 134th and Singapore ranks 134th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.